title: Proteomics approaches: new technologies and clinical applications in breast carcinomas.
abstract: Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The advent of proteomics provides the hope of discovering novel biological markers that can be used for early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast.
  
  
  BACKGROUND
  Breast cancer is a major health problem and one of the leading causes of death among women worldwide. Its incidence is steadily rising in developing countries. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year(1). Invasive carcinomas represent 70-80% of all breast cancer and among these, infiltrating ductal carcinomas (IDCA) are the most aggressive forms and have a poor prognosis(2). Histopathologically identical breast cancers show a different biological behavior in terms of aggressiveness, progression, and response to therapy. Thus, there is a great need for new breast cancer biomarkers that might help detect this cancer at an earlier stage, to uncover prognostically distinct subclasses, and to provide best individual treatment(2). Currently, the search for specific cancer-related alterations are largely carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Two dimensional gel electrophoresis coupled with mass spectrometry constitute a new proteomics based paradigm for detecting disease in pathology specimens and monitoring disease response to therapy. This review describes these proteomics technologies and their application in the analysis of breast carcinoma.
authors.affiliation: Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Tunisia. bechrhamrita@yahoo.fr
authors.forename: B
authors.initials: B
authors.lastname: Hamrita
authors.forename: H B
authors.initials: HB
authors.lastname: Nasr
authors.forename: K
authors.initials: K
authors.lastname: Chahed
authors.forename: L
authors.initials: L
authors.lastname: Chouchane
mesh_terms: D000595:Amino Acid Sequence; D001943:Breast Neoplasms / Q000737:chemistry* / Q000175:diagnosis; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D008969:Molecular Sequence Data; D040901:Proteomics / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization